FLR-101
Pre-clinical- Indications
- Antibiotic-associated microbiome disruption
Company intelligence / Profile preview
Florey Biosciences
Boston, Massachusetts, United Statesfloreybiosciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Florey Biosciences has developed a lead program, FLR‑101, an engineered yeast that produces an enzyme to break down beta-lactam antibiotics in the gut. This approach aims to protect the microbiome during antibiotic treatment without interfering with systemic infection control. The company is preparing preclinical safety studies and aims to launch its flagship product within three years if development proceeds as planned[3].
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Engineered probiotics (genetically modified yeast)Microbial therapeuticsProtein delivery via microbes[1][3][5][7]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seerave Ventures/Foundation (strategic investor and board representation)[5]
Beyond the preview
Go deeper on Florey Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Florey Biosciences.